Publications by authors named "R Douglas McEvoy"
Background: Sleep-disordered breathing (SDB) is common in patients with atrial fibrillation (AF) and negatively impacts treatment outcomes. Optimal tools for AF patient selection for SDB testing are lacking.
Objectives: This study sought to develop and validate a prediction tool to detect patients who have AF with moderate-to-severe SDB.
Article Synopsis
- A study was conducted using Medicare data to evaluate the effectiveness of a third COVID-19 vaccine dose among beneficiaries aged 65 and older during the Omicron variant surge.
- The results showed that 73.3% of the eligible individuals had received a third dose by March 2022, and it significantly reduced the risk of hospitalization and death, especially within the first 60 days.
- However, the added protection from the third dose declined after four months, highlighting the importance of ongoing vaccination efforts.
Study Objectives: Insomnia is a highly prevalent and debilitating disorder. Cognitive behavioral therapy for insomnia (CBTi) is the recommended 'fist line' treatment, but is accessed by a minority of people with insomnia. This paper describes a system-level implementation program to improve access to CBTi in Australia to inform CBTi implementation in other locations.
View Article and Find Full Text PDFSleep disorders are common, and largely undiagnosed in early-career workers. The combination of sleep disorders and shift work has implications for mental health, workplace safety, and productivity. Early identification and management of sleep disorders is likely to be beneficial to workers, employers and the community more broadly.
View Article and Find Full Text PDFImportance: Active monitoring of health outcomes after COVID-19 vaccination provides early detection of rare outcomes that may not be identified in prelicensure trials.
Objective: To conduct near-real-time monitoring of health outcomes after COVID-19 vaccination in the US pediatric population.
Design, Setting, And Participants: This cohort study evaluated 21 prespecified health outcomes after exposure before early 2023 to BNT162b2, mRNA-1273, or NVX-CoV2373 ancestral monovalent COVID-19 vaccines in children aged 6 months to 17 years by applying a near-real-time monitoring framework using health care data from 3 commercial claims databases in the US (Optum [through April 2023], Carelon Research [through March 2023], and CVS Health [through February 2023]).